82 related articles for article (PubMed ID: 1851602)
21. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
Planting AS; van der Burg ME; Goey SH; Schellens JH; Vecht C; de Boer-Dennert M; Stoter G; Verweij J
Eur J Cancer; 1996 Oct; 32A(11):2026-8. PubMed ID: 8943692
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis.
Chary KK; Higby DJ; Henderson ES; Swinerton KD
Cancer Treat Rep; 1977; 61(3):367-70. PubMed ID: 266972
[TBL] [Abstract][Full Text] [Related]
23. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Buzaid AC; Murren JR; Durivage HJ
Cancer; 1991 Sep; 68(6):1238-41. PubMed ID: 1873775
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.
Margolin KA; Doroshow JH; Akman SA; Leong LA; Morgan RJ; Somlo G; Raschko J; Pereira C; Yonemoto L; Ahn C
J Clin Oncol; 1992 Oct; 10(10):1574-8. PubMed ID: 1403037
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
Presant CA; Bartolucci AA; Ungaro P; Oldham R
Cancer Treat Rep; 1979 Aug; 63(8):1367-9. PubMed ID: 476710
[TBL] [Abstract][Full Text] [Related]
26. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.
Eton O; Bajorin DF; Chapman PB; Cody BV; Houghton AN
Invest New Drugs; 1991 Feb; 9(1):101-3. PubMed ID: 2026478
[TBL] [Abstract][Full Text] [Related]
28. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
Verschraegen CF; Kleeberg UR; Mulder J; Rumke P; Truchetet F; Czarnetzki B; Rozencweig M; Thomas D; Suciu S
Cancer; 1988 Sep; 62(6):1061-5. PubMed ID: 3409184
[TBL] [Abstract][Full Text] [Related]
29. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.
Feliu J; González Barón M; Chacón JI; Espinosa E; Garrido P; Castro J; Escobar Y; Colmenarejo A; Jara C; García Girón C; Espinosa J; Ordóñez A
Cancer Chemother Pharmacol; 1996; 38(2):191-4. PubMed ID: 8616911
[TBL] [Abstract][Full Text] [Related]
30. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Ramnath N; LoRusso P; Simon M; Martino S
Am J Clin Oncol; 1997 Aug; 20(4):368-72. PubMed ID: 9256891
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma.
Bedikian AY; Legha SS; Eton O; Buzaid AC; Papadopoulos N; Plager C; McIntyre S; Viallet J
Anticancer Drugs; 1999 Sep; 10(8):735-9. PubMed ID: 10573206
[TBL] [Abstract][Full Text] [Related]
32. [Combination of platidiam and bleomycetin in disseminated skin melanoma].
Garin AM; Zharkov SA; Lichinitser MR; Khlebnov AV
Antibiot Med Biotekhnol; 1985 Oct; 30(10):780-3. PubMed ID: 2418776
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.
McClay EF; McClay MT; Monroe L; Jones JA; Winski PJ
Melanoma Res; 2001 Jun; 11(3):309-13. PubMed ID: 11468521
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma.
Bedikian AY; Legha SS; Eton O; Buzaid AC; Papadopoulos N; Coates S; Simmons T; Neefe J; von Roemeling R
Ann Oncol; 1997 Apr; 8(4):363-7. PubMed ID: 9209666
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.
Bukowski RM; Murthy SA; Finke J; Caulfield MJ; Tubbs R; Herzog P; Stanley J; Edinger M; Tuason L; McLain D
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):273-82. PubMed ID: 8061900
[TBL] [Abstract][Full Text] [Related]
36. High-dose cisplatin in disseminated melanoma: a comparison of two schedules.
Mortimer JE; Schulman S; MacDonald JS; Kopecky K; Goodman G
Cancer Chemother Pharmacol; 1990; 25(5):373-6. PubMed ID: 2306798
[TBL] [Abstract][Full Text] [Related]
37. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
Woolley PV; Ayoob MJ; Smith FP; Dritschilo A
J Clin Oncol; 1983 Mar; 1(3):198-203. PubMed ID: 6321681
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of gallium nitrate in patients with advanced malignant melanoma.
Casper ES; Stanton GF; Sordillo PP; Parente R; Michaelson RA; Vinceguerra V
Cancer Treat Rep; 1985 Sep; 69(9):1019-20. PubMed ID: 4028034
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma.
Oratz R; Hauschild A; Sebastian G; Schadendorf D; Castro D; Bröcker EB; Orenberg EK
Melanoma Res; 2003 Feb; 13(1):59-66. PubMed ID: 12569286
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.
Iscoe NA; Eisenhauer EA; Bodurtha AJ
Invest New Drugs; 1990 Feb; 8(1):121-3. PubMed ID: 2140563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
